As people grow older changes occur in their immune system, which is clearly one of our major protections against the hazards of a very dangerous world. There is debate as to whether immune responsiveness is deficient in older people, but there is general agreement that as people grow older the immune system shows many signs of dysfunction. One of the most troublesome is the appearance of auto-immune disease. The pathogenesis of these diseases is complex, and most certainly involves a complex development in which there is a continuous interplay between gene expression and responses to an hazardous environment.
One particular hazard from which we will never free ourselves, is the damage induced by reactive species of oxygen. This hazard is the inevitable consequence of being aerobic organisms. These chemically reactive oxygen species damage membrane lipids, carbohydrates, proteins and most significantly they damage the cellular DNA. This is particularly dangerous because we carry only two copies of each DNA molecule in our cells, and therefore irretrievable loss of information from our DNA is a constant danger for aerobic organisms. As one might reasonably expect, evolution, mutation and natural selection has produced organisms with multiple and sophisticated mechanisms of DNA repair. In general, these mechanisms are very efficient; our neurones can sometimes survive for over 100 years without dividing and without succumbing to this continuous damage from dangerous chemicals.
The repair systems include one pathway that is specifically adapted to repair damage to the DNA bases, which it achieves by removing the damaged base. The DNA strand is then broken, one or two nucleotides are replaced and then the DNA chain is rejoined. This pathway includes a complex element, which while not required, it seems, for the basic process, does make this repair pathway much more efficient. This element is the nuclear enzyme poly (ADP-ribose) polymerase, which is a very abundant nuclear protein, found in all nucleated cells. It is curious because it is stimulated to be enzymatically active exclusively by DNA strand-breaks which occur during DNA damage and repair. The enzyme then synthesises a polymer of ADP-ribose, which consists of repeating units of ADP-ribose and is similar to, yet different from real polynucleotide polymers such as RNA or DNA, having two phosphates joined one-to-another instead of just one, as in real polynucleotides. Moreover, the enzyme is also unusual in using as a substrate, the enzyme cofactor NAD+. Poly (ADP-ribose) is usually found covalently associated with the enzyme protein itself. The precise function of this enzyme is not clearly understood, although it is known to have a role in making base-excision repair more efficient and in preventing biologically undesirable DNA recombination events. It seems that this enzyme is involved in nearly all occasions when DNA strands are broken and then rejoined, except for elementary DNA synthesis.
So, what has all this to do with auto immune diseases and specifically with lupus? About 20 years ago, at my suggestion, Dr T Sugimura and his colleagues examined the serum of patients with lupus and found that these sera very frequently displayed specific, high-affinity antibodies to this strange polymer, poly (ADP-ribose)'.
Since then, numerous clinical reports have confirmed and extended this original result2. Extensive and careful studies by DA Isenberg and coworkers3°4 have shown that antibodies to poly (ADP-ribose) in the serum of SLE patients is an excellent complement to the more conventional demonstration of anti-DNA antibodies.
The test compound, radio-labelled poly (ADP-ribose) is somewhat easier to prepare pure than is radio-labelled double-stranded DNA completely free of singlestranded DNA; the latter often confuses the results by binding to numerous irrelevant serum proteins. Isenberg has also published two further results of interest; it turns out that antibodies to poly (ADP-ribose) are not unique to lupus, but are found, albeit at a lower frequency, in other auto immune diseases such as Sj6gren's syndrome, scleroderma and in rheumatoid arthritis. Of some interest is their observation that these antibodies are also found in some cases of persons infected with Klebsiella, with E. coli and with leprosy. Antibodies to poly (ADP-ribose) are also very frequently found in the sera of auto immune mice.
It has been pointed out that because drug-induced lupus erythematosus (DLE) is triggered by known compounds, analysis of this type of lupus may lead to a better understanding of the development of SLE 5. Antibodies to poly (ADP-ribose) are also observed in patients with drug-induced lupus. Recently, it has been demonstrated that neutrophils can transform lupusinducing drugs, such as procainamide and hydralazine, to cytotoxic compounds'. It has also been shown, as would then be expected, that these compounds activate poly (ADP-ribose) polymerase'. It seems that poly (ADP-ribose) polymerase is also involved in the development of drug-induced lupus.
Although antibodies to poly (ADP-ribose) are almost never found in normal controls ( < 2%), such antibodies are observed in almost half of asymptomatic relatives of persons who have been diagnosed as suffering from SLE8. This result implies that at least in some patients, inheritance of certain alleles (forms) of the gene for poly (ADP-ribose) polymerase, might increase the risk of developing SLE in later life.
Further evidence of this inherited susceptibility to develop SLE was produced by Haug et a19. They determined that in persons with the diagnosis of familial SLE, the enzymatic synthesis of poly (ADP-ribose) was decreased to about 30% of controls; and very strikingly, asymptomatic family members also showed a decrease in the enzymatic synthesis of poly (ADP-ribose) in the circulating lymphocytes (to about 70%). In this study it was shown that family members had an increased prevalence of antinuclear antibodies. These authors have therefore also concluded that poly (ADP-ribose) polymerase activity may be an inherited trait which may be one of the significant factors in determining genetic susceptibility to develop SLE.
A report in this issue of Lupus by H-Y Chen and colleagues [pages 14-21], continues this exploration and confirms that enzymatic synthesis of poly (ADP-ribose) is indeed lowered in the circulating lymphocytes of patients with lupus, to almost half of the value in the control group. These authors have investigated the reason for this decreased enzymatic activity and have demonstrated that the basic mechanism of polymer synthesis is not altered in these patients; but, it seems that the number of active molecules of the enzyme may be decreased in SLE. Such a result may be caused by a decrease in the synthesis of enzyme molecules or by the inactivation of preformed, active enzyme molecules. The amount of enzyme as determined by Western immunoblotting seems to be the same in both sets of samples, and therefore the specific enzyme activity in SLE patients is about 30 to 40% of the controls. The authors conclude that the enzyme may be defective or inactive in SLE. It should be said that there has been a recent report in this journal that concludes that there are decreased mRNA levels coding for poly (ADP-ribose) polymerase in lymphocytes of patients with SLEIO. There are at least two possible reasons for this discrepancy ; firstly, the activities of the enzyme that were measured may have been different, and secondly, the composition of the cell populations measured in the two reports may have been different. Figure 3 in Chen et al, in this issue raises the question whether their population of SLE patients was bimodal, with some patients having a normal poly (ADP-ribose) polymerase activity and a second group with a markedly lowered activity. If this were true, it might imply that only a proportion of SLE patients develop SLE because of the lowered activity of this enzyme. In either event, the lowered enzyme activity reported by Chen et al is of considerable interest. It has been reported by Grube & Biirkle&dquo; that there is a good correlation between the specific enzyme activity of poly (ADP-ribose) polymerase and the maximum lifespan of a wide range of animal species. If a deficient poly (ADP-ribose) polymerase contributes to an increased likelihood of developing an auto immune disease like SLE, it may also be an important risk factor for a shortened life-span. It will be important to determine whether specific alleles (forms) of this enzyme are indeed associated with an increased frequency of lupus (and other auto immune diseases) and also with a prematurely shortened life-span. The work we have discussed makes an investigation of the expression of the gene for poly (ADP-ribose) polymerase very urgent. Moreover, discovery of alleles of this gene with different specific enzyme activity is also very important.
Examination of
Recent work by MK O'Farrell and G de Murcia and colleagues 12 has described the isolation of a very strange single-base change mutation in this gene which increases the specific enzyme activity remarkably; this makes it clear that mutations are possible which specifically alter the specific enzyme activity of poly (ADPribose) polymerase; such alleles in the population may contribute to familial susceptibility to SLE. In addition, we must not forget the possibility that accumulated, unrepaired damage to either the gene or the protein may also contribute to the observed decrease in poly (ADP-ribose) polymerase activity in SLE. Finally, there is always the problem in this disease whether any observed alteration is part of the later development of symptoms or is really part of the significant, early pathogenesis of this disease. The evidence seems to indicate that poly (ADP-ribose) may well play an important part in the early pathogenesis of lupus.
